JP2010513229A5 - - Google Patents

Download PDF

Info

Publication number
JP2010513229A5
JP2010513229A5 JP2009540327A JP2009540327A JP2010513229A5 JP 2010513229 A5 JP2010513229 A5 JP 2010513229A5 JP 2009540327 A JP2009540327 A JP 2009540327A JP 2009540327 A JP2009540327 A JP 2009540327A JP 2010513229 A5 JP2010513229 A5 JP 2010513229A5
Authority
JP
Japan
Prior art keywords
composition
composition according
acetaminophen
acetylcysteine
blockers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009540327A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010513229A (ja
Filing date
Publication date
Priority claimed from US11/952,556 external-priority patent/US20080139654A1/en
Application filed filed Critical
Publication of JP2010513229A publication Critical patent/JP2010513229A/ja
Publication of JP2010513229A5 publication Critical patent/JP2010513229A5/ja
Withdrawn legal-status Critical Current

Links

JP2009540327A 2006-12-09 2007-12-08 軽減された肝毒性を含む最小限に抑制された副作用を有するアセトアミノフェン組成物 Withdrawn JP2010513229A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87374306P 2006-12-09 2006-12-09
US11/952,556 US20080139654A1 (en) 2006-12-09 2007-12-07 Acetaminophen compositions having minimized side effects including reduced hepatotoxicity
PCT/US2007/025167 WO2008073344A1 (en) 2006-12-09 2007-12-08 Acetaminophen compositions having minimized side effects including reduced hepatotoxicity

Publications (2)

Publication Number Publication Date
JP2010513229A JP2010513229A (ja) 2010-04-30
JP2010513229A5 true JP2010513229A5 (enExample) 2010-06-17

Family

ID=39498949

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009540327A Withdrawn JP2010513229A (ja) 2006-12-09 2007-12-08 軽減された肝毒性を含む最小限に抑制された副作用を有するアセトアミノフェン組成物

Country Status (13)

Country Link
US (1) US20080139654A1 (enExample)
EP (1) EP2094253A4 (enExample)
JP (1) JP2010513229A (enExample)
KR (1) KR20090089867A (enExample)
CN (1) CN101588797A (enExample)
AU (1) AU2007332812A1 (enExample)
BR (1) BRPI0721216A2 (enExample)
CA (1) CA2671490A1 (enExample)
EA (1) EA200970449A1 (enExample)
IL (1) IL199056A0 (enExample)
MX (1) MX2009006177A (enExample)
WO (1) WO2008073344A1 (enExample)
ZA (1) ZA200904764B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20080187A1 (it) * 2008-02-07 2009-08-08 Velleja Res Srl Formulazioni di amminoacidi per la prevenzione del danno epatico da paracetamolo
US20110014285A1 (en) * 2009-07-15 2011-01-20 Herzenberg Leonore A N-acetyl cysteine compositions and methods to improve the therapeutic efficacy of acetaminophen
TR201007652A2 (tr) * 2010-09-20 2012-04-24 Bi̇lgi̇ç Mahmut Sinerjik etki.
WO2013044085A1 (en) * 2011-09-23 2013-03-28 Subramanian Veerappan Sellappan A solid, edible, chewable laxative composition
WO2014159994A1 (en) * 2013-03-13 2014-10-02 Nbip, Llc Compositions and methods for removing the odor from glutathione when mixed in an aqueous system
US10104882B2 (en) * 2013-04-29 2018-10-23 Montefiore Medical Center Methods and compositions for preventing and treating electrophile-mediated toxicities
ITMI20130874A1 (it) * 2013-05-29 2014-11-30 Zambon Spa Compresse deglutibili di n-acetilcisteina
AU2017208123B2 (en) * 2016-01-11 2022-04-21 Egetis Therapeutics Ab Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions
KR101962518B1 (ko) 2016-09-13 2019-03-26 울산대학교 산학협력단 일산화탄소 또는 일산화탄소 공급체를 유효성분으로 함유하는 아세트아미노펜 유도 간 독성 예방 또는 치료용 조성물
WO2018089400A1 (en) * 2016-11-09 2018-05-17 The Feinstein Institute For Medical Research Iguratimod as an mif inhibitor
KR102813413B1 (ko) 2019-08-27 2025-05-27 주식회사 엘지에너지솔루션 단위셀의 두께측정장치 및 두께측정방법
US11590090B2 (en) * 2019-09-14 2023-02-28 Anzen Pharmaceuticals, LLC Acetaminophen formulation with protection against toxic effects of overdose
EP4238559A1 (en) 2022-03-04 2023-09-06 Centre Hospitalier Universitaire de Caen Normandie Combinations of acetaminophen and n-acetyl cysteine for the treatment of pain and fever

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474757A (en) * 1992-10-16 1995-12-12 Rutgers University Prevention of acetaminophen overdose toxicity with organosulfur compounds
GR1002731B (el) * 1996-10-21 1997-07-04 Uni-Pharma ����� ������ �.�.�.�. ������������ ���������� Φαρμακευτικα ενεσιμα διαλυματα περιεχοντα συνδυασμους παρακεταμολης με αλλες δραστικες ουσιες.
DE19651551C2 (de) * 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
US6566401B2 (en) * 2001-03-30 2003-05-20 The Board Of Trustees Of The Leland Stanford Junior University N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
US6863901B2 (en) * 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration

Similar Documents

Publication Publication Date Title
JP2010513229A5 (enExample)
NZ586751A (en) Use of CDDO methyl ester (methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate) for the treatment of renal diseases and for improving kigney function
JP2013147511A5 (enExample)
JP2013505205A5 (enExample)
WO2009082459A2 (en) Anti-aging composition containing resveratrol and method of administration
JP2015524408A5 (enExample)
NZ625592A (en) Compositions and methods for the treatment of hepatic diseases and disorders
JP2012533565A5 (enExample)
WO2007095091A3 (en) Oral delivery of therapeutic agents using tight junction agonists
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
KR20160033796A (ko) 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형
RU2014145931A (ru) Композиция для лечения нарушений метаболизма
JP2005528430A5 (enExample)
RU2019138166A (ru) Средство для профилактики или лечения атрофии головного мозга
FI3706724T3 (fi) Suun kautta otettavia rifamysiini sv -koostumuksia
WO2006023630A3 (en) The use of n-aryl diazaspiracyclic compounds in the treatment of addiction
MX2010002192A (es) Compuesto de tetrahidroquinolina que antagonizan el receptor tsh.
JP2012504584A5 (enExample)
CA2688047A1 (en) Composition of biocompatible microparticles of alginic acid for the controlled release of active ingredients by intravenous administration
BR112012022052A2 (pt) método para o tratamento ou prevenção de sintomas da variação hormonal, composição farmacêutica para o tratamento ou prevenção de sintomas da variação hormonal e kit para o tratamento ou prevenção de sintomas da variação hormonal
RU2015150303A (ru) Композиция, содержащая гидрокортизон
JP2012506429A5 (enExample)
JP2020536098A5 (enExample)
JP2015518002A5 (enExample)
RU2017137008A (ru) Антагонисты толл-подобного рецептора 4 и применение при аутоиммунных заболеваниях печени